Streetbeat News

Stock Prices

LPCN

Lipocine Inc. reported that its LPCN 1148 Phase 2 Study met its primary endpoint in patients with cirrhosis, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:49 am

BCS

EBAY

EW

EYE

LC

MXL

NOVA

OII

PI

PKX

SIMO

TPIC

VEON

Several stocks are recording losses in today's pre-market trading session. TPI Composites, National Vision Holdings, LendingClub Corporation, Oceaneering International, Impinj, MaxLinear, VEON Ltd., Silicon Motion Technology Corporation, POSCO Holdings, Sunnova Energy International, eBay, Edwards Lifesciences Corporation, and Barclays PLC all saw declines. Reasons for the declines include lowered forecasts, ending partnerships, weaker-than-expected quarterly results, downbeat sales, and downbeat second-quarter results.

Portfolio Pulse from Lisa Levin

July 27, 2023 | 10:47 am

LAZ

Lazard (NYSE:LAZ) reported Q2 adjusted earnings of $0.24 per share, beating the analyst consensus estimate of $0.10 by 140%. However, this is a 73.91% decrease from the same period last year. The company also reported quarterly sales of $620.03 million, beating the analyst consensus estimate of $567.99 million by 9.16%, but this is an 8.27% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:47 am

BSX

Boston Scientific has provided its Q3 FY23 revenue growth guidance of 8.5%-10.5% (reported) and 7%-9% (organic). The company also forecasts an adjusted EPS of $0.46-$0.48, which is in line with the consensus of $0.48.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:43 am

BSX

Boston Scientific has revised its FY23 revenue growth guidance to 10.5%-11.5% (reported) and 10%-11% (organic), up from the previously expected 8.5%-10.5% and 8%-10%. The company also forecasts an adjusted EPS of $1.96-$2.00, higher than the consensus of $1.95 and prior guidance of $1.90-$1.96.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:41 am

NOC

Northrop Grumman has revised its FY23 MTM-Adjusted EPS outlook from $22.25-$22.85 to $22.45-$22.85.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:40 am

CBZ

CBIZ has reaffirmed its outlook for FY23 adjusted EPS of $2.36-$2.41, in line with consensus estimates. The company has also increased its 2023 revenue growth expectations to 10%-12%, up from the previous guidance of 8%-10%.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:37 am

WEX

WEX Inc. has projected its Q3 revenue to be between $629M and $639M, compared to an estimate of $635.36M. The company also expects its adjusted EPS to be between $3.65 and $3.75, versus an estimate of $3.66.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:37 am

TXT

Textron has raised its FY23 outlook, now expecting adjusted earnings per share from continuing operations to be in the range of $5.20 to $5.30, up from the previous outlook of $5.00 to $5.20. The company reiterated its expectation for cash flow from continuing operations of the manufacturing group before pension contributions of $0.9 billion to $1.0 billion.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:36 am

LUV

Southwest Airlines expects its third quarter 2023 CASM-X (Cost per Available Seat Mile excluding fuel and oil expense) to increase between 3.5% and 6.5% year-over-year, primarily due to ongoing inflationary cost pressures.

Portfolio Pulse from Bill Haddad

July 27, 2023 | 10:35 am